Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An increased level of Lp(a) lipoprotein has been identified as a risk factor for coronary artery disease that is highly heritable. The genetic determinants of the Lp(a) lipoprotein level and their relevance for the risk of coronary disease are incompletely understood. METHODS: We used a novel gene chip containing 48,742 single-nucleotide polymorphisms (SNPs) in 2100 candidate genes to test for associations in 3145 case subjects with coronary disease and 3352 control subjects. Replication was tested in three independent populations involving 4846 additional case subjects with coronary disease and 4594 control subjects. RESULTS: Three chromosomal regions (6q26-27, 9p21, and 1p13) were strongly associated with the risk of coronary disease. The LPA locus on 6q26-27 encoding Lp(a) lipoprotein had the strongest association. We identified a common variant (rs10455872) at the LPA locus with an odds ratio for coronary disease of 1.70 (95% confidence interval [CI], 1.49 to 1.95) and another independent variant (rs3798220) with an odds ratio of 1.92 (95% CI, 1.48 to 2.49). Both variants were strongly associated with an increased level of Lp(a) lipoprotein, a reduced copy number in LPA (which determines the number of kringle IV-type 2 repeats), and a small Lp(a) lipoprotein size. Replication studies confirmed the effects of both variants on the Lp(a) lipoprotein level and the risk of coronary disease. A meta-analysis showed that with a genotype score involving both LPA SNPs, the odds ratios for coronary disease were 1.51 (95% CI, 1.38 to 1.66) for one variant and 2.57 (95% CI, 1.80 to 3.67) for two or more variants. After adjustment for the Lp(a) lipoprotein level, the association between the LPA genotype score and the risk of coronary disease was abolished. CONCLUSIONS: We identified two LPA variants that were strongly associated with both an increased level of Lp(a) lipoprotein and an increased risk of coronary disease. Our findings provide support for a causal role of Lp(a) lipoprotein in coronary disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, genetic studies found a causal link between elevated Lp(a) levels and a higher risk for CVD diseases,[184–189] and vice versa [190].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [185]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“[Statement]Hyper-Lp(a)-lipoproteinemia is a risk factor for ASCVD. (Evidence level: E-1a)”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [227]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We found the association between LDLR genotype and Lp(a) levels remained significant after accounting for the rs10455872 genotype that tags a narrower range of LPA alleles10, but we could not directly assess LPA KIV2 copy number variants in the UKBB cohort to assess for a difference between groups.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Multiple genome-wide association studies (GWAS) did not find an association between Lp(a) levels and common variants at the LDLR locus10,46,47, but a recent GWAS of 371,212 individuals in the UK Biobank did48.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“Higher plasma Lp(a) concentrations are associated with an increased risk of ASCVD, but it appears to be a much weaker risk factor for most people than LDL-C [72,73].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [73]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Genomic Control for Association Studies
Devlin, B., & Roeder, K. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00997.x · Cited by 3,162
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants
Scott, L. J., Mohlke, K. L., Bonnycastle, L. L., Willer, C. J., Li, Y., Duren, W. L., Erdos, M. R., Stringham, H. M., Chines, P. S., Jackson, A. U., et al. (2007) · Science · doi:10.1126/science.1142382 · Cited by 2,753
Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes
Zeggini, E., Weedon, M. N., Lindgren, C. M., Frayling, T. M., Elliott, K. S., Lango, H., Timpson, N. J., Perry, J. R. B., Rayner, N. W., Freathy, R. M., et al. (2007) · Science · doi:10.1126/science.1142364 · Cited by 2,194
Genomewide Association Analysis of Coronary Artery Disease
Samani, N. J., Erdmann, J., Hall, A. S., Hengstenberg, C., Mangino, M., Mayer, B., Dixon, R. J., Meitinger, T., Braund, P., Wichmann, H.-E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072366 · Cited by 2,044
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction
Helgadottir, A., Thorleifsson, G., Manolescu, A., Gretarsdottir, S., Blondal, T., Jonasdottir, A., Jonasdottir, A., Sigurdsson, A., Baker, A., Palsson, A., et al. (2007) · Science · doi:10.1126/science.1142842 · Cited by 1,594
A Common Allele on Chromosome 9 Associated with Coronary Heart Disease
McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A., Roberts, R., Cox, D. R., Hinds, D. A., Pennacchio, L. A., Tybjaerg-Hansen, A., Folsom, A. R., et al. (2007) · Science · doi:10.1126/science.1142447 · Cited by 1,587
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Self-citationCommon variants at 30 loci contribute to polygenic dyslipidemia
Kathiresan, S., Willer, C. J., Peloso, G. M., Demissie, S., Musunuru, K., Schadt, E. E., Kaplan, L., Bennett, D., Li, Y., Tanaka, T., et al. (2009) · Nature Genetics · doi:10.1038/ng.291 · Cited by 1,364
Self-citation
Research works printed but not linked: 1
- Siekmeier R, 1996, Lab Medizin, 20, 294
Cited by
Items 601–700 of 1,004
Lipoprotein(a) Where Do We Stand? From the Physiopathology to Innovative Terapy
Iannuzzo, G., Tripaldella, M., Mallardo, V., Morgillo, M., Vitelli, N., Iannuzzi, A., Aliberti, E., Giallauria, F., Tramontano, A. L., Carluccio, R., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9070838 · Cited by 35
“Moreover, in contrast to other lipoproteins characterized by constant masses, Lp(a) also presents different isoforms of various sizes inversely related to its plasma concentration [70].”
BackgroundLipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma
Uccello, M., Malaguarnera, G., Pelligra, E. M., Biondi, A., Basile, F., & Motta, M. (2011) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/0971-5851.89775 · Cited by 31
“[32-34] Moreover, recent data indicate that Lp(a) is a cardiovascular risk factor independent of traditional ones, such as LDL cholesterol, low HDL cholesterol levels, hypertension, diabetes mellitus, obesity, sedentary, and smoking.[35,36] In some cancer types, apart from HCC, Lp(a) plasma levels have been found to b…”
BackgroundRosenson, R. S., Tate, A. M., Grushko, O. G., Damodaran, D., Chen, Q., Boffa, M. B., Koschinsky, M. L., Narula, J., & Goonewardena, S. N. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100820 · Cited by 30
“Mendelian randomization studies suggest an independent, causal relationship be-tween elevated Lp(a) levels and ASCVD risk (2, 6 – 8).”
Defining the Role of Lipoprotein Apheresis in the Management of Familial Hypercholesterolemia
Lee, W. P., Datta, B. N., Ong, B. B., Rees, A., & Halcox, J. (2011) · American Journal of Cardiovascular Drugs · doi:10.2165/11594970-000000000-00000 · Cited by 30
Katsiki, N., Filippatos, T. D., Vlachopoulos, C. V., Panagiotakos, D. B., Milionis, H. J., Tselepis, A. D., Garoufi, A., Rallidis, L. S., Richter, D. J., Nomikos, T., et al. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.01.004 · Cited by 29
Kronenberg, F. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12207 · Cited by 29
Cai, A., Li, L., Zhang, Y., Mo, Y., Li, Z., Mai, W., & Zhou, Y. (2013) · Disease Markers · doi:10.1155/2013/472845 · Cited by 29
“Hindawi Publishing Corporation Disease Markers Volume 35 (2013), Issue 6, Pages 857–862 http://dx.doi.org/10.1155/2013/472845”
BackgroundInfluentialGenetic Risk Scores Predict Recurrence of Acute Coronary Syndrome
Vaara, S. M., Tikkanen, E., Parkkonen, O., Lokki, M., Ripatti, S., Perola, M., Nieminen, M. S., & Sinisalo, J. P. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.115.001271 · Cited by 30
Whayne, T. F. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180123112956 · Cited by 32
Muhanhali, D., Zhai, T., Ling, Y., & Gao, X. (2018) · Journal of Lipid Research · doi:10.1194/jlr.p082792 · Cited by 31
“SNPs at the LPA locus, like rs10455872 and rs3798220, were also associated with an increased level of Lp(a) (13, 14).”
BackgroundMolecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?
Ward, N. C., Kostner, K., SULLIVAN, D. R., Nestel, P. J., & Watts, G. F. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122073 · Cited by 32
Roth, C., Krychtiuk, K. A., Gangl, C., Schrutka, L., Distelmaier, K., Wojta, J., Hengstenberg, C., Berger, R., & Speidl, W. S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227054 · Cited by 29
“This is in line with results from the LURIC study [9] and supports mendelian randomization [22] and population based studies [7] that showed an increased prevalence and a more severe disease in subjects with elevated levels of Lp(a).”
ResultCausal Effect of Lipids and Lipoproteins on Atherosclerosis
Ference, B. A. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.001 · Cited by 28
Sosnowska, B., Toth, P. P., Razavi, A. C., Remaley, A. T., Blumenthal, R. S., & Banach, M. (2025) · Archives of Medical Science · doi:10.5114/aoms/202213 · Cited by 36
“In addition to apo(a) isoform size, which is encoded by the LPA gene, other genetic variants, such as single nucleotide polymorphisms (SNPs), also determine Lp(a) serum levels [23, 24].”
Koschinsky, M. L., & Boffa, M. B. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.08.002 · Cited by 33
Kullo, I. J., Trejo-Gutiérrez, J. F., López-Jiménez, F. A., Thomas, R. J., Allison, T. G., Mulvagh, S. L., Arruda-Olson, A. M., Hayes, S. N., Pollak, A. W., Kopecky, S. L., et al. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.06.018 · Cited by 28
“In contrast to several novel risk factors (including hs-CRP), Lp(a) has a causal role in ASCVD, as illustrated in a mendelian randomization study that found that genetic variants that increase Lp(a) levels are associated with adverse ASCVD events.(67) Elevated levels appear to contribute to familial clustering of CHD(…”
BackgroundSingh, S. S., Rashid, M., Lieverse, A. G., Kronenberg, F., Lamina, C., Mulder, M. T., de Rijke, Y. B., Sijbrands, E. J. G., & van Hoek, M. (2020) · Diabetologia · doi:10.1007/s00125-020-05120-9 · Cited by 28
“Furthermore, two well investigated LPA SNPs, rs10455872 and rs3798220 influence Lp(a) plasma levels, and are associated with a lower number of Lp(a) KIV repeats [12].”
BackgroundLipid-lowering therapy and percutaneous coronary interventions
Koskinas, K. C., Mach, F., & Räber, L. (2021) · EuroIntervention · doi:10.4244/eij-d-20-00999 · Cited by 32
Lipoprotein(a), a Lethal Player in Calcific Aortic Valve Disease
Hu, J., Lei, H. C., Liu, L., & Xu, D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.812368 · Cited by 28
Elevated lipoprotein(a) and genetic polymorphisms in the LPA gene may predict cardiovascular events
Gu, J.-X., Huang, J., Li, S.-S., Zhou, L.-H., Yang, M., Yang, L., Zhang, A., Yin, Y., Zhang, N., Jia, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07596-4 · Cited by 28
“Exclusion criteria included: (1) percutaneous coronary intervention within the previous three months, (2) acute coronary syndrome within the previous six months, (3), history of coronary artery bypass operation, (4) chronic heart failure, cardiomyopathy, valvular heart disease, (5) pulmonary heart disease, (6) severe…”
BackgroundMethodWilliams, L. H., Baker-Smith, C. M., Bolick, J. P., Carter, J., Kirkpatrick, C. F., Ley, S. L., Peterson, A. L. H., SHAH, A. S., Sikand, G., Ware, A. L., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.07.011 · Cited by 30
Lipoprotein(a)-related cardiovascular and all-cause mortalities in Korean adults
Kim, B. J., Lee, M. Y., Choi, H., Kwon, M., & Kang, J. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac271 · Cited by 28
Khalifa, M. A., Noureen, A., Ertelthalner, K., Bandegi, A. R., Delport, R., Firdaus, W. J. J., Geethanjali, F. S., Luthra, K., Makemaharn, O., Pang, R. W. C., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.015 · Cited by 30
Donnelly, L. A., van Zuydam, N. R., Zhou, K., Tavendale, R., Carr, F., der Zee, A. H. M., Leusink, M., de Boer, A., Doevendans, P. A., Asselbergs, F. W., et al. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283642fd6 · Cited by 28
Cho, J. H., Lee, W., Lee, E. S., Kim, J., Park, S. E., Park, C., Lee, W., Oh, K.-W., Park, H., & Rhee, E. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.219 · Cited by 29
Mendelian randomization: Its impact on cardiovascular disease
Kawashiri, M., Tada, H., Nomura, A., & Yamagishi, M. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.04.007 · Cited by 29
Genome‐Wide Association Study of Coronary Artery Disease
Ogawa, N., Imai, Y., Morita, H., & Nagai, R. (2010) · International Journal of Hypertension · doi:10.4061/2010/790539 · Cited by 28
“All the six causative genetic regions are related to inflammatory process in vasculature and are thought to contribute to the process in atherosclerotic changes through its inflammatory functions and thus increase the risk of MI.”
BackgroundKarwatowska-Prokopczuk, E., Clouet-Foraison, N., Xia, S., Viney, N. J., Witztum, J. L., Marcovina, S. M., & Tsimikas, S. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.036 · Cited by 27
Monogenic and Polygenic Models of Coronary Artery Disease
Muse, E. D., Chen, S.-F., & Torkamani, A. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01540-0 · Cited by 27
Mendelian Randomization and Type 2 Diabetes
Swerdlow, D. I. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6638-5 · Cited by 27
“The relevance of lipoprotein(a) (Lp(a)) to cardiovascular disease has been demonstrated by MR studies [41], although a specific pharmacological Lp(a) inhibitor has not yet entered”
BackgroundThe role of Lipoprotein(a) in cardiovascular disease: Current concepts and future perspectives
Vavuranakis, M., Jones, S. R., Cardoso, R. N., Gerstenblith, G., & Leucker, T. M. (2020) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2020.09.016 · Cited by 29
“The LPA gene genetically determines the variance in Lp(a) plasma concentrations, ranging from 36% in the PROCARDIS consortium (21) to 70%−90% in genome wide association studies, with larger apo(a) isoforms associated with lower concentrations of Lp(a) (22, 23).”
BackgroundNakamura, H., Kataoka, Y., Nicholls, S. J., Puri, R., Kitahara, S., Murai, K., Sawada, K., Matama, H., Iwai, T., Honda, S., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.03.033 · Cited by 28
Tao, J., Yang, X., Qiu, Q., Gao, F., Chen, W., Hu, L., Xu, Y., Yi, Y., Hu, H., & Jiang, L. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01728-5 · Cited by 30
Use of Lipoprotein(a) to improve diagnosis and management in clinical familial hypercholesterolemia
Tromp, T. R., Ibrahim, S., Nurmohamed, N. S., Peter, J., Zuurbier, L. C., Defesche, J. C., Reeskamp, L. F., Hovingh, G. K., & Stroes, E. S. G. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.11.020 · Cited by 27
Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option
Maloberti, A., Fabbri, S., Colombo, V., Gualini, E., Monticelli, M., Daus, F., Busti, A., Galasso, M., Censi, L. D., Algeri, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010170 · Cited by 32
“The relationship between Lp(a) and CV events has been well established in epidemiological and GWAS studies [9,10] as well as in meta-analyses [4,5] and it is considered the strongest single genetic risk factor known for CV diseases [36].”
BackgroundResultZhang, H., Zhang, Y., Tian, T., Wang, T., Chen, J., Yuan, J., Qian, J., Hu, F., Dou, K., Qiao, S., et al. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.05.094 · Cited by 28
Medeiros, A. M., Alves, A. C., Miranda, B., Chora, J. R., Bourbon, M., Bourbon, M., Rato, Q., Alves, A. C., Medeiros, A. M., Gomes, A. C., et al. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100490 · Cited by 30
“The LPA genetic score results from the sum of the risk alleles of the two SNPs (C for rs3798220 and G for rs10455872) previously described (27).”
BackgroundSarzani, R., Spannella, F., Pentima, C. D., Giulietti, F., Landolfo, M., & Allevi, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010328 · Cited by 31
“Lp(a) is a lipoprotein associated with an increased risk of ischemic heart disease [20], causally involved in atherosclerosis [21,22] and calcific valvular aortic stenosis [23].”
BackgroundHung, M., & Tsimikas, S. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000131 · Cited by 27
“They may also include patients with the presence of one or more abnormal copies of LPA snps associated with elevated Lp(a) levels [2].”
BackgroundHigh Lipoprotein(a) Concentrations Are Associated with Impaired Endothelial Function in Children
Lapinleimu, J., Raitakari, O. T., Lapinleimu, H., Pahkala, K., Rönnemaa, T., Simell, O., & Viikari, J. S. A. (2015) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2014.12.051 · Cited by 27
Ma, Q., Ozel, A. B., Ramdas, S., McGee, B. M., Khoriaty, R. N., Siemieniak, D. R., Li, H.-D., Guan, Y., Brody, L. C., Mills, J. L., et al. (2014) · Blood · doi:10.1182/blood-2014-03-560086 · Cited by 27
Kim, J. J., Chae, S. J., Choi, Y. M., Hwang, K. R., Song, S. H., Yoon, S. H., Kim, S. M., Ku, S., Kim, S. H., Kim, J. G., et al. (2013) · Human Reproduction · doi:10.1093/humrep/det057 · Cited by 28
“Genetic factors are major contributors to variation in plasma lipoprotein (a) concentrations, which remains stable over an individual’s lifespan (Clarke et al., 2009; Li et al., 2011; Dube et al., 2012).”
BackgroundZabaneh, D., Kumari, M., Sandhu, M., Wareham, N., Wainwright, N., Papamarkou, T., Hopewell, J., Clarke, R., Li, K., Palmen, J., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.015 · Cited by 25
“A second study the Human CVD bead chip, similar to our study, confirmed the impact of the LPA locus and especially the Kringle IV copy number variants (13), and the strong effect of these variants on risk of Coronary Heart Disease (CHD).”
BackgroundSelf-citationLipoprotein (a): Coming of Age at Last
Witztum, J. L., & Ginsberg, H. N. (2016) · Journal of Lipid Research · doi:10.1194/jlr.e066985 · Cited by 28
Lipoprotein apheresis: present and future uses
Moriarty, P. M. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000234 · Cited by 27
“Epidemiology, Mendelian, and genetic data have associated high levels of lipoprotein(a) with CVD risk [13,14].”
BackgroundBeheshtian, A., Shitole, S. G., Segal, A. Z., Leifer, D., Tracy, R. P., Rader, D. J., Devereux, R. B., & Kizer, J. R. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.013 · Cited by 27
Balashanmugam, M. V., Thippeswamy, B. S., Nagarethinam, S., Vastrad, B. M., & Vastrad, C. M. (2019) · Biomolecules · doi:10.3390/biom10010035 · Cited by 29
“Polymorphism in genes such as MT1A [85], MT2A [86], CYP2C9 [87], CYP3A4 [88], fibrinogen beta chain (FGB) [89], ADH1C [90], lipoprotein, Lp(a) (LPA) [91] and APOC3 [92] were liable for advancement of CAD.”
Pederiva, C., Capra, M. E., Biasucci, G., Banderali, G., Fabrizi, E., Gazzotti, M., Casula, M., & Catapano, A. L. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.021 · Cited by 27
Cui, K., Yin, D., Zhu, C., Song, W., Wang, H., Jia, L., Zhang, R., Wang, H., Cai, Z., Feng, L., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023578 · Cited by 26
Lipoprotein(a) distribution and its association with carotid arteriopathy in the Chinese population
Lin, L., Deng, K., Chen, Z., Lei, F., Qin, J., Huang, X., Sun, T., Zhang, X., Hu, Y., Zhang, P., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.007 · Cited by 26
Franchini, M., Capuzzo, E., & Liumbruno, G. M. (2016) · Europe PMC (PubMed Central) · doi:10.2450/2015.0163-15 · Cited by 26
Genetics of Dyslipidemia and Ischemic Heart Disease
Sharma, K., & Baliga, R. R. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0855-9 · Cited by 26
Liu, H., Cao, Y., Jin, J., Hua, Q., Li, Y., Guo, Y., Zhu, C., Wu, N., Dong, Q., & Li, J. (2021) · Hypertension Research · doi:10.1038/s41440-021-00668-4 · Cited by 27
Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients
Kwon, S. W., Lee, B. K., Hong, B., Kim, J., Choi, E., Sung, J. M., Rhee, J.-H., Park, Y. M., Ma, D. W., Chung, H., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.05.007 · Cited by 26
“Over the past few years, major advances have been made in understanding the causal role of elevated Lp(a) in premature cardiovascular disease [4,5].”
BackgroundRecent Updates of Lipoprotein(a) and Cardiovascular Disease
Liu, T., Yoon, W.-S., & Lee, S. R. (2021) · Chonnam Medical Journal · doi:10.4068/cmj.2021.57.1.36 · Cited by 26
Chiesa, G., Zenti, M. G., Baragetti, A., Barbagallo, C. M., Borghi, C., Colivicchi, F., Maggioni, A. P., Noto, D., Pirro, M., Rivellese, A. A., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.07.019 · Cited by 27
Evidence of dependence of lipoprotein(a) on triglyceride and high-density lipoprotein metabolism
Konerman, M. C., Kulkarni, K. R., Toth, P. P., & Jones, S. R. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.08.004 · Cited by 25
Navarro-Millán, I. Y., & Curtis, J. R. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32835fc62e · Cited by 25
“lipoprotein (a) [39], a risk factor known to be associated with vascular events, occurred more frequently in TCZ-treated patients compared with placebo patients.”
ResultLPA genotype is associated with premature cardiovascular disease in familial hypercholesterolemia
Paquette, M., Bernard, S., Thanassoulis, G., & Baass, A. W. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.04.006 · Cited by 26
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Miname, M. H., Rocha, V. Z., & Santos, R. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00936-1 · Cited by 26
Sex-specific differences in effect size estimates at established complex trait loci
Orozco, G., Ioannidis, J. P. A., Morris, A. P., & Zeggini, E. (2012) · International Journal of Epidemiology · doi:10.1093/ije/dys104 · Cited by 25
Worldwide Increasing Use of Nonfasting Rather Than Fasting Lipid Profiles
Langsted, A., & Nordestgaard, B. G. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvae046 · Cited by 24
Actualización en cardiopatía isquémica
Bardají, A., Barrabés, J. A., Sanchis, J. M., & Sanchez, P. L. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70140-8 · Cited by 27
Onat, A., Çoban, N., Can, G., Yüksel, M., Karagöz, A., Yüksel, H., Ademoğlu, E., & Erginel‐Ünaltuna, N. (2014) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0034-1385922 · Cited by 24
Lipoprotein(a) Testing Patterns in a Large Health System
Kelsey, M. D., Page, C. B., Alhanti, B., Rhodes, S. L., Kent, S. T., Peterson, E. D., & Pagidipati, N. J. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.05.018 · Cited by 24
Littmann, K., Hagström, E., Häbel, H., Bottai, M., Eriksson, M., Parini, P., & Brinck, J. W. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab016 · Cited by 24
Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factor
Koschinsky, M. L., Stroes, E. S. G., & Kronenberg, F. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106843 · Cited by 25
A multilocus genetic risk score predicts coronary heart disease risk in a Chinese Han population
Gui, L., Wu, F., Han, X., Dai, X., Qiu, G., Li, J., Wang, J., Zhang, X., Wu, T., & He, M. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.09.032 · Cited by 25
Romagnuolo, I., Sticchi, E., Attanasio, M., Grifoni, E., Cioni, G., Cellai, A. P., Abbate, R., & Fatini, C. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.01.014 · Cited by 25
Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype
Sanin, V., Pfetsch, V., & Köenig, W. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0869-3 · Cited by 31
Guo, Y., Wang, F., Li, L., Gao, H., Arckacki, S., Wang, I. Z., Barnard, J., Ellis, S. G., Hubbard, C. A., Topol, E. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05381-2 · Cited by 26
Cohort profile: role of lipoproteins in cardiovascular disease—the LipidCardio study
König, M., Joshi, S., Leistner, D. M., Landmesser, U., Sinning, D., Steinhagen‐Thiessen, E., & Demuth, I. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030097 · Cited by 24
Using Mendelian randomization to determine causative factors in cardiovascular disease
Johansen, C. T., & Hegele, R. A. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02586.x · Cited by 24
Enkhmaa, B., Anuurad, E., Zhang, W., & Berglund, L. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.04.035 · Cited by 24
Tadin‐Strapps, M., Robinson, M., LeVoci, L., Andrews, L. E., Yendluri, S., Williams, S., Bartz, S., & Johns, D. G. (2015) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-014-9605-1 · Cited by 25
“The genetic factors which determine Lp(a) levels include copy number variants of KIV type 2, a pentanucleotide repeat in the LPA promoter that modulates gene expression, variations in RNA splicing, and several single nucleotide polymorphisms located within structural and functional domains [3, 4, 6, 7].”
Scipione, C. A., McAiney, J., Simard, D. J., Bazzi, Z., Gemin, M., Romagnuolo, R., Macrae, F. L., Ariëns, R. A. S., Hegele, R. A., Auld, J., et al. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13759 · Cited by 23
Jiang, X., Xu, J., Hao, X., Xue, J., Li, K., Jin, A., Lin, J., Meng, X., Zheng, L., & Wang, Y. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02359-w · Cited by 23
“Lp(a) has attracted considerable attention because of its several large clinical genetic observation studies, which confirmed that plasma Lp(a) level is positively associated with increased risks of stroke, [2] myocardial infarction [3, 4], and aortic valve stenosis [1, 5, 6].”
BackgroundThe Inherited Hypercholesterolemias
Loh, W. J., & Watts, G. F. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.006 · Cited by 24
Wang, Z., Li, M., Li, J., & Liu, N. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.09.010 · Cited by 23
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment
Wulff, A. B., Nordestgaard, B. G., & Langsted, A. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01192-9 · Cited by 24
“…the publication of results showing that genetic variants in the Lp(a) coding gene LPA were associated with increased plasma levels of Lp(a) and risk of coronary disease [4] including myocardial infarction [5], which thereby largely proved the causal involvement of Lp(a) in cardiovascular disease.”
Hosseini, K., Soleimani, H., Maleki, S., Nasrollahizadeh, A., Tayebi, S., Nelson, J. R., & Heffron, S. P. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04057-w · Cited by 25
“Researchers have recently investigated the impact of lipoproteins other than LDL-C in MACE reduction, including Lp(a) and Apo B [39–41].”
BackgroundLPA Gene Polymorphisms and Gene Expression Associated with Coronary Artery Disease
Song, Z., Cao, H., Wu, H., Zhou, L., & Qin, L. (2017) · BioMed Research International · doi:10.1155/2017/4138376 · Cited by 23
“Clarke showed that LPA gene variants were strongly associated with both an increased plasma levels of Lp(a) and an increased risk of coronary disease [7].”
BackgroundNucleic Acid Therapies for Ischemic Stroke
Henninger, N., & Mayasi, Y. M. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00710-x · Cited by 24
Ihdayhid, A. R., Goeller, M., Dey, D., Nerlekar, N., Yap, G., Thakur, U., Adams, D., Cameron, J. D., SENEVIRATNE, S. K., Achenbach, S. S., et al. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.06.020 · Cited by 23
Wu, Z., Sheng, H., Chen, Y., Tang, J., Liu, Y., Chen, Q., Lu, L., & Jin, W. (2014) · PubMed · Cited by 23
Lipoprotein(a) is not related to markers of insulin resistance in pregnancy
Todoric, J., Handisurya, A., Leitner, K., Harreiter, J., Hoermann, G., & Kautzky‐Willer, A. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-138 · Cited by 23
Use of Emerging Lipoprotein Risk Factors in Assessment of Cardiovascular Risk
Grundy, S. M. (2012) · JAMA · doi:10.1001/jama.2012.6896 · Cited by 25
Herbal approaches to system dysfunctions
(2013) · Elsevier eBooks · doi:10.1016/b978-0-443-06992-5.00009-8 · Cited by 22
Mitsis, A., Khattab, E., Kyriakou, M., Sokratous, S., Sakellaropoulos, S., Tzikas, S., Kadoglou, N. P. E., & Kassimis, G. (2025) · Biomedicines · doi:10.3390/biomedicines13071723 · Cited by 24
“Genetic variations in the LPA gene, particularly SNPs such as rs3798220 and rs10455872, are associated with elevated Lp(a) concentrations and a greater likelihood of atherosclerosis [17,35–37].”
Florentin, M., Elisaf, M., Rizos, C. V., Nikolaou, V., Bilianou, E., Pitsavos, C. E., & Liberopoulos, E. N. (2016) · Lipids · doi:10.1007/s11745-016-4216-z · Cited by 23
“In addition, large genetic studies using the Mendelian randomization approach demonstrated that Lp(a) levels are continuously and linearly related to the risk of developing CVD [16, 17].”
BackgroundInfluentialZhu, P., Tang, X., Song, Y., Zhang, Y., Gao, L., Gao, Z., Chen, J., Yang, Y., Gao, R.-L., Xu, B., et al. (2020) · Platelets · doi:10.1080/09537104.2020.1802412 · Cited by 22
Владиславович, Е. М., Shalnova, S. A., Yarovaya, E. B., Kutsenko, V. A., Евстифеева, С. Е., Metelskaya, V. A., Drapkina, O. M., & Boytsov, S. A. (2021) · Archives of Medical Science · doi:10.5114/aoms/131089 · Cited by 22
“Arch Med Sci 7 The link between Lp(a) and IHD and its complications, including MI, has been established in many studies [2, 3, 9] and subsequently summarized [5, 7].”
BackgroundLipoprotein(a): Just an Innocent Bystander in Arterial Hypertension?
Brosolo, G., Porto, A. D., Marcante, S., Picci, A., Capilupi, F., Capilupi, P., Bulfone, L., Vacca, A., Bertin, N., Vivarelli, C., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713363 · Cited by 23
New insights into the therapeutic options to lower lipoprotein(a)
Baragetti, A., Dalt, L. D., & Norata, G. D. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14254 · Cited by 24
Clarke, S. L., Huang, R. D. L., Hilliard, A. T., Levin, M. G., Sharma, D., Thomson, B., Lynch, J. A., Tsao, P. S., Gaziano, J. M., Assimes, T. L., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae271 · Cited by 25
Lin, J. J., Khetarpal, S. A., Terembula, K., Reilly, M. P., & Wilson, F. P. (2015) · BMC Nephrology · doi:10.1186/s12882-015-0122-5 · Cited by 22
“Both Lp(a) and apoC-III levels have recently been identified as genetic causal risk factors for CV disease, [5 – 7 The purpose of this study was to probe whether baseline circulating Lp(a) and apoC-III levels are associated with the development of renal impairment in type 2 diabetes mellitus (T2DM)…”
InfluentialThe mysterious lipoprotein(a) is still good for a surprise
Lamina, C., & Kronenberg, F. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70085-8 · Cited by 22
Lipoprotein(a) as a therapeutic target in cardiovascular disease
Koschinsky, M. L., & Boffa, M. B. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.920326 · Cited by 24
“A third key study published that year by Clarke and colleagues [14] utilizing a candidate gene Article highlights.”
BackgroundCoronary Artery Disease: Why We should Consider the Y Chromosome
Molina, E., Clarence, E. M., Ahmady, F., Chew, G. S., & Charchar, F. J. (2016) · Heart Lung and Circulation · doi:10.1016/j.hlc.2015.12.100 · Cited by 23
Warden, B. A., Minnier, J., Watts, G. F., Fazio, S., & Shapiro, M. D. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.04.008 · Cited by 22
Metadata
- Authors
- Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., Bennett, D., Silveira, A., Malarstig, A., Green, F. R., Lathrop, M., Gigante, B., Leander, K., de Faire, U., Seedorf, U., Hamsten, A., Collins, R., Watkins, H., & Farrall, M.
- Affiliations
- University of Oxford (GB)
- Centre for Human Genetics (GB)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- Mario Negri Institute for Pharmacological Research (IT)
- University of Münster (DE)
- University of Surrey (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-24
- Volume
- 361
- Issue
- 26
- Pages
- 2518-2528
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2098230963
- Cited by
- 1,671
- References
- 40
- Citations by year
- 2026: 129 · 2025: 134 · 2024: 121 · 2023: 124 · 2022: 133 · 2021: 103 · 2020: 101 · 2019: 96 · 2018: 75 · 2017: 90 · 2016: 103 · 2015: 90 · 2014: 82 · 2013: 73 · 2012: 88
- FWCI
- 73.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
- Funders
- Wellcome Trust
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- coronary artery disease, LPA gene, single nucleotide polymorphisms, rs10455872, rs3798220, genetic association, 9p21
- MeSH terms
- Coronary Disease, Genetic Markers, Genotype, Humans, Myocardial Infarction, Regression Analysis, Risk Factors, Likelihood Functions, Case-Control Studies, Lipoprotein(a), Kringles, Genetic Predisposition to Disease, Oligonucleotide Array Sequence Analysis, Polymorphism, Single Nucleotide, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.